Table 1.

Overview of the FcRn receptors.

Agent	Company	Molecule	Current status
Efgartigimod	ARGENX	Humanized IgG1 Fc Fragment	Approved for treatment of AChR+ gMG
Rozanolixizumab	UCB	Humanized IgG4 Monoclonal	Phase 3 completed
Nipocalimab	Johnson and Johnson	Humanized aglycosylated monoclonal ab	Phase 3 study ongoing
Batoclimab	Immunovant	Humanized IgG1 monoclonal ab	Phase 3 study ongoing
ABY-039	Affibody	Bilvalent antibody	Phase 1 study was prematurely terminated